RIS Rx Welcomes Industry Pioneer Tom Doyle as Senior Advisor

Pharmaceutical distribution and biopharma services leader joins RIS Rx as the company accelerates GTN Revenue Protection across the pharmaceutical industry

IRVINE, Calif.--(BUSINESS WIRE)--RIS Rx, the healthcare technology company delivering real-time GTN Revenue Protection for the world's leading pharmaceutical manufacturers, today announced that Tom Doyle has joined the organization as Senior Advisor. Doyle, a widely respected executive with decades of leadership across pharmaceutical distribution, services, and outsourced commercialization, will provide strategic guidance as RIS Rx continues to expand its footprint across the industry.

Tom brings an extraordinary track record to his new role. He spent several years at Cencora Biopharma Services in senior executive leadership, including serving as SVP and Chief Customer Officer. Throughout his tenure, he led teams focused on integrating the full spectrum of Cencora's global capabilities to enhance patient outcomes. Prior to Cencora, he served as SVP of Program Leadership at EVERSANA, spearheading the launch of outsourced commercialization services and overseeing a team of Chief Commercial Officers. Earlier, as EVP of Commercial Solutions at H.D. Smith, he led the company's expansion into 3PL, specialty distribution, and patient services - including the acquisition of Triplefin, which accelerated growth in the patient support space.

"Tom is one of the most respected minds in this industry," said Gerard Rivera, Co-founder and CEO of RIS Rx. "Stephen and I have admired his work for more than a decade. He has an extraordinary ability to recognize problems worth solving and people committed to solving them. Having him as a strategic advisor as we continue to grow our GTN Revenue Protection capabilities is an incredible addition for our team and for our clients."

Stephen Hom, Co-founder, EVP and COO of RIS Rx, echoed the sentiment: "Tom has always pushed us to think bigger and act with more conviction. He understands the complexity of this industry - the GTN leakage problem, the blind spots manufacturers face, the gap between what they invest in patient affordability and what patients actually receive. His perspective at this stage of RIS Rx's growth is exactly what we need."

For Doyle, the decision was clear. "Seldom in your career do you encounter a business with a 95 Net Promoter Score," said Tom Doyle, Senior Advisor at RIS Rx. "That number reflects something real - a team that is genuinely solving problems and doing it in a way that earns trust. I've watched Gerard and Stephen build RIS Rx from the outside for years. Being part of what RIS Rx is doing in GTN Revenue Protection, at this moment in the industry, is exactly where I want to be."

Doyle's arrival comes as RIS Rx continues to gain momentum across the pharmaceutical industry, having protected more than $1 billion in annual revenue for its clients through proprietary real-time analytics, pharmacist-led expertise, and patient segmentation capabilities that prevent GTN leakage before it occurs. His appointment underscores the company's commitment to building the most experienced advisory team in the GTN Revenue Protection space.

Tom will be on the ground with the RIS Rx team at Asembia AXS26 in Las Vegas over the coming week.

About RIS Rx

RIS Rx is a healthcare technology company delivering real-time gross-to-net (GTN) revenue protection for the world’s leading pharmaceutical manufacturers. Through proprietary software, real-time analytics and pharmacist-led expertise, RIS Rx helps clients optimize operations, eliminate leakage and ensure that financial assistance reaches the patients who need it most. The company has protected more than $1 billion in annual revenue for its customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands. Learn more at www.RISRx.com.